Takeda Pharmaceutical Co ADR (NYSE:TAK) currently has a daily average trading volume of 2.19M but it saw 1459754 shares traded in last market. With a market cap of 45.18B USD, the company’s current market price of $14.32 came rising about 0.28 while comparing to the previous closing price of $14.28. In past 52 weeks, the stock remained buoying in the range of price level as high as $15.47 and as low as $12.57. In the recent trading on the day, stock has struck highest price mark of $14.195 while lowest mark touched by it was $14.33.
Taking a look at 20-day trading activity of Takeda Pharmaceutical Co ADR (TAK) gives us an average price of $14.72, while its current price level is -7.43% below from 52-week high level whereas it is 13.88% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $14.46 while that of 200 days or SMA-200 reads an average of $13.99. A closer look into the stock’s movement over the week reveals that its volatility is standing at 1.11% during that period while stretching the period over a month that decreases to 0.96%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.95 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BofA Securities which upgraded the stock as “Buy” in its note to investors issued on March 16, 2023, recommending a price target of $20 for it. Cowen upgraded its recommendation for the stock as a “Outperform” from “Market Perform” on July 19, 2022 while assigning a price target range of $21-$24.
Over the week, TAK’s stock price is moving -1.78% down while it is -4.02% when we observe its performance for the past one month. Year-to-date it is 0.35% up and over the past year, the stock is showing a downside performance of -6.28%.
The company is expected to be releasing its next quarterly report on 2024-Oct-31, for which analysts forecasted an EPS of 0.61 while estimate for next year EPS is 0.47. In next quarter, company is expected to be making quarterly sales of $8.04M as analysts are expecting the sales for current fiscal year at $30.83M and seeing the company making $31.86M in sales next year. Moreover, analysts are in estimates of $7.57M for current-quarter revenue.
Currently, Takeda Pharmaceutical Co ADR’s total number of outstanding shares is 3.16B. Company’s return on investment (ROI) stands at 1.22% and return on equity (ROE) at 2.02%. It has a price to earnings ratio (P/E ratio) of 46.92 while having a 31.01 of forward P/E ratio. Stock’s beta reads 0.57. Stock has a price to book (P/B) ratio of 0.93 while price to sale or P/S ratio amounts to 1.53. Its return on asset (ROA) is 0.96% on average.
